{"result": "(\"entity\"<|>AACE/ACE<|>ORGANIZATION<|>AACE/ACE refers to the American Association of Clinical Endocrinologists and the American College of Endocrinology, which provide guidelines for managing dyslipidemia and cardiovascular disease prevention.)\n##\n(\"entity\"<|>EPA<|>ORGANIZATION<|>EPA stands for Eicosapentaenoic Acid, an omega-3 fatty acid found in fish oil, used in high doses to treat hypertriglyceridemia.)\n##\n(\"entity\"<|>DHA<|>ORGANIZATION<|>DHA stands for Docosahexaenoic Acid, another omega-3 fatty acid found in fish oil, known for its health benefits.)\n##\n(\"entity\"<|>LIPOPROTEINS<|>ORGANIZATION<|>Lipoproteins are large molecules made of fat and protein that transport lipids in the bloodstream, including VLDL, LDL, and HDL.)\n##\n(\"entity\"<|>VLDL<|>ORGANIZATION<|>Very Low-Density Lipoprotein (VLDL) is a type of lipoprotein that carries triglycerides and cholesterol in the blood.)\n##\n(\"entity\"<|>LDL<|>ORGANIZATION<|>Low-Density Lipoprotein (LDL) is often referred to as \"bad cholesterol\" and is associated with an increased risk of cardiovascular disease.)\n##\n(\"entity\"<|>HDL<|>ORGANIZATION<|>High-Density Lipoprotein (HDL) is known as \"good cholesterol\" and helps remove other forms of cholesterol from the bloodstream.)\n##\n(\"entity\"<|>TRIGLYCERIDES<|>ORGANIZATION<|>Triglycerides are a type of fat found in the blood, and high levels can increase the risk of heart disease.)\n##\n(\"entity\"<|>HYPERTRIGLYCERIDEMIA<|>EVENT<|>Hypertriglyceridemia is a condition characterized by elevated levels of triglycerides in the blood, which can lead to cardiovascular issues.)\n##\n(\"entity\"<|>ECV<|>EVENT<|>ECV refers to cardiovascular events, which include conditions like unstable angina and heart attacks.)\n##\n(\"entity\"<|>STATINS<|>ORGANIZATION<|>Statins are a class of drugs used to lower cholesterol levels in the blood and reduce the risk of cardiovascular disease.)\n##\n(\"entity\"<|>FRCV<|>ORGANIZATION<|>FRCV stands for Framingham Risk Score for Cardiovascular Disease, a tool used to estimate the risk of cardiovascular events.)\n##\n(\"relationship\"<|>AACE/ACE<|>STATINS<|>AACE/ACE provides guidelines for the treatment of dyslipidemia, including the use of statins<|>8)\n##\n(\"relationship\"<|>EPA<|>HYPERTRIGLYCERIDEMIA<|>EPA is used in high doses to treat hypertriglyceridemia<|>7)\n##\n(\"relationship\"<|>DHA<|>HYPERTRIGLYCERIDEMIA<|>DHA is used in high doses to treat hypertriglyceridemia<|>7)\n##\n(\"relationship\"<|>VLDL<|>TRIGLYCERIDES<|>VLDL is rich in triglycerides and is responsible for transporting them in the bloodstream<|>6)\n##\n(\"relationship\"<|>LDL<|>ECV<|>High levels of LDL are associated with an increased risk of cardiovascular events<|>9)\n##\n(\"relationship\"<|>HDL<|>ECV<|>Higher levels of HDL are associated with a lower risk of cardiovascular events<|>9)\n##\n(\"relationship\"<|>TRIGLYCERIDES<|>ECV<|>Elevated triglycerides are a risk factor for cardiovascular events<|>8)\n##\n(\"relationship\"<|>STATINS<|>LDL<|>Statins are used to lower LDL cholesterol levels<|>8)\n##\n(\"relationship\"<|>FRCV<|>ECV<|>FRCV is used to assess the risk of cardiovascular events<|>7)\n<|COMPLETE|>", "input": "\n-Goal-\nGiven a text document that is potentially relevant to this activity and a list of entity types, identify all entities of those types from the text and all relationships among the identified entities.\n \n-Steps-\n1. Identify all entities. For each identified entity, extract the following information:\n- entity_name: Name of the entity, capitalized\n- entity_type: One of the following types: [organization,person,geo,event]\n- entity_description: Comprehensive description of the entity's attributes and activities\nFormat each entity as (\"entity\"<|><entity_name><|><entity_type><|><entity_description>)\n \n2. From the entities identified in step 1, identify all pairs of (source_entity, target_entity) that are *clearly related* to each other.\nFor each pair of related entities, extract the following information:\n- source_entity: name of the source entity, as identified in step 1\n- target_entity: name of the target entity, as identified in step 1\n- relationship_description: explanation as to why you think the source entity and the target entity are related to each other\n- relationship_strength: a numeric score indicating strength of the relationship between the source entity and target entity\n Format each relationship as (\"relationship\"<|><source_entity><|><target_entity><|><relationship_description><|><relationship_strength>)\n \n3. Return output in English as a single list of all the entities and relationships identified in steps 1 and 2. Use **##** as the list delimiter.\n \n4. When finished, output <|COMPLETE|>\n \n######################\n-Examples-\n######################\nExample 1:\nEntity_types: ORGANIZATION,PERSON\nText:\nThe Verdantis's Central Institution is scheduled to meet on Monday and Thursday, with the institution planning to release its latest policy decision on Thursday at 1:30 p.m. PDT, followed by a press conference where Central Institution Chair Martin Smith will take questions. Investors expect the Market Strategy Committee to hold its benchmark interest rate steady in a range of 3.5%-3.75%.\n######################\nOutput:\n(\"entity\"<|>CENTRAL INSTITUTION<|>ORGANIZATION<|>The Central Institution is the Federal Reserve of Verdantis, which is setting interest rates on Monday and Thursday)\n##\n(\"entity\"<|>MARTIN SMITH<|>PERSON<|>Martin Smith is the chair of the Central Institution)\n##\n(\"entity\"<|>MARKET STRATEGY COMMITTEE<|>ORGANIZATION<|>The Central Institution committee makes key decisions about interest rates and the growth of Verdantis's money supply)\n##\n(\"relationship\"<|>MARTIN SMITH<|>CENTRAL INSTITUTION<|>Martin Smith is the Chair of the Central Institution and will answer questions at a press conference<|>9)\n<|COMPLETE|>\n\n######################\nExample 2:\nEntity_types: ORGANIZATION\nText:\nTechGlobal's (TG) stock skyrocketed in its opening day on the Global Exchange Thursday. But IPO experts warn that the semiconductor corporation's debut on the public markets isn't indicative of how other newly listed companies may perform.\n\nTechGlobal, a formerly public company, was taken private by Vision Holdings in 2014. The well-established chip designer says it powers 85% of premium smartphones.\n######################\nOutput:\n(\"entity\"<|>TECHGLOBAL<|>ORGANIZATION<|>TechGlobal is a stock now listed on the Global Exchange which powers 85% of premium smartphones)\n##\n(\"entity\"<|>VISION HOLDINGS<|>ORGANIZATION<|>Vision Holdings is a firm that previously owned TechGlobal)\n##\n(\"relationship\"<|>TECHGLOBAL<|>VISION HOLDINGS<|>Vision Holdings formerly owned TechGlobal from 2014 until present<|>5)\n<|COMPLETE|>\n\n######################\nExample 3:\nEntity_types: ORGANIZATION,GEO,PERSON\nText:\nFive Aurelians jailed for 8 years in Firuzabad and widely regarded as hostages are on their way home to Aurelia.\n\nThe swap orchestrated by Quintara was finalized when $8bn of Firuzi funds were transferred to financial institutions in Krohaara, the capital of Quintara.\n\nThe exchange initiated in Firuzabad's capital, Tiruzia, led to the four men and one woman, who are also Firuzi nationals, boarding a chartered flight to Krohaara.\n\nThey were welcomed by senior Aurelian officials and are now on their way to Aurelia's capital, Cashion.\n\nThe Aurelians include 39-year-old businessman Samuel Namara, who has been held in Tiruzia's Alhamia Prison, as well as journalist Durke Bataglani, 59, and environmentalist Meggie Tazbah, 53, who also holds Bratinas nationality.\n######################\nOutput:\n(\"entity\"<|>FIRUZABAD<|>GEO<|>Firuzabad held Aurelians as hostages)\n##\n(\"entity\"<|>AURELIA<|>GEO<|>Country seeking to release hostages)\n##\n(\"entity\"<|>QUINTARA<|>GEO<|>Country that negotiated a swap of money in exchange for hostages)\n##\n##\n(\"entity\"<|>TIRUZIA<|>GEO<|>Capital of Firuzabad where the Aurelians were being held)\n##\n(\"entity\"<|>KROHAARA<|>GEO<|>Capital city in Quintara)\n##\n(\"entity\"<|>CASHION<|>GEO<|>Capital city in Aurelia)\n##\n(\"entity\"<|>SAMUEL NAMARA<|>PERSON<|>Aurelian who spent time in Tiruzia's Alhamia Prison)\n##\n(\"entity\"<|>ALHAMIA PRISON<|>GEO<|>Prison in Tiruzia)\n##\n(\"entity\"<|>DURKE BATAGLANI<|>PERSON<|>Aurelian journalist who was held hostage)\n##\n(\"entity\"<|>MEGGIE TAZBAH<|>PERSON<|>Bratinas national and environmentalist who was held hostage)\n##\n(\"relationship\"<|>FIRUZABAD<|>AURELIA<|>Firuzabad negotiated a hostage exchange with Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>AURELIA<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>QUINTARA<|>FIRUZABAD<|>Quintara brokered the hostage exchange between Firuzabad and Aurelia<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>ALHAMIA PRISON<|>Samuel Namara was a prisoner at Alhamia prison<|>8)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>MEGGIE TAZBAH<|>Samuel Namara and Meggie Tazbah were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>DURKE BATAGLANI<|>Samuel Namara and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>DURKE BATAGLANI<|>Meggie Tazbah and Durke Bataglani were exchanged in the same hostage release<|>2)\n##\n(\"relationship\"<|>SAMUEL NAMARA<|>FIRUZABAD<|>Samuel Namara was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>MEGGIE TAZBAH<|>FIRUZABAD<|>Meggie Tazbah was a hostage in Firuzabad<|>2)\n##\n(\"relationship\"<|>DURKE BATAGLANI<|>FIRUZABAD<|>Durke Bataglani was a hostage in Firuzabad<|>2)\n<|COMPLETE|>\n\n######################\n-Real Data-\n######################\nEntity_types: organization,person,geo,event\nText: úa inhibiendo la absorción de colesterol y fitoesteroles\n         aminoácidos responsables de la unión al receptor de LDL.                                                                        (como el sitosterol), a nivel intestinal, por su unión con la proteína NPC1L1 (Niemann-Pick\n                                                                                                                                         C1-like 1). Se puede usar en monoterapia, aunque mayoritariamente se usa en combinación\n         Lipoproteínas de muy baja densidad (VLDL)                                                                                       con estatinas, cuando no se consigue alcanzar los objetivos terapéuticos. En monoterapia\n         Son partículas grandes, poco densas y ricas en lípidos. Están compuestas por un 55% de                                          proporciona una reducción del colesterol LDL del 18-20%, una reducción de los triglicéridos\n         triglicéridos, un 20% de colesterol y un 15% de fosfolípidos. Su apolipoproteína distintiva es                                  del 5-14% y un aumento del colesterol HDL del 1-5%. Las reducciones de los lípidos plasmá-\n         la apo B-100 y también contienen apo E, apo C-I, C-II y C-III.                                                                  ticos, en combinación con estatinas, se muestran en la tabla 6.\n\n\n\n460                                                                                                                                                                                                                                                                  461\n---\n                                                                                                                                                                                                                  OBESIDAD,               LÍPIDOS                      8\n                                                                                                                                                                                     Y TRASTORNOS ELECTROLÍTICOS\n\n\n\n     Tabla 6. Grupos de riesgo y objetivos de tratamiento según las guías de manejo de la                                                        Los ácidos grasos ω-3 (ácido eicosapentaenoico o EPA y ácido docosahexaenoico o DHA)\n     dislipidemia y prevención de la enfermedad cardiovascular de la AACE/ACE (2017)                                                             son componentes del aceite de pescado y han sido utilizados en dosis altas en el trata-\n                                                                                                                                                 miento de la hipertrigliceridemia. El mecanismo de acción no es del todo conocido, pero en\n       CATEGORÍA            FACTORES DE RIESGO/RIESGO CV A                    OBJETIVOS DE TRATAMIENTO (mg/dl)                                   parte es por su habilidad para interaccionar con los PPAR y por reducir la secreción de apo\n       DE RIESGO            10 AÑOS                                               cLDL        Col. no-HDL         apo B                          B. Su efecto predominante es la disminución de los triglicéridos (20-45%). El efecto sobre\n                            • ECV progresiva, incluyendo angina                                                                                  otros parámetros lipídicos es de menor cuantía: incremento leve del colesterol HDL del 5%\n                              inestable, en individuos con                                                                                       y escaso efecto sobre el colesterol LDL.\n       Riesgo                 cLDL < 70 mg/dl\n       extremo              • Historia de ECV prematura (<55 años                 <55             <80              <70                           Referencias:\n                              en hombres, <65 en mujeres)                                                                                        • Amor Fernández AJ, Vinagre Torres I, Perea Castilla V. Manual de Endocrinología y Nutrición [Internet]. Madrid: Sociedad Española\n                            • ECV en pacientes con diabetes, HFH o                                                                                 de Endocrinología y Nutrición; 2018. Capítulo 125. Tratamiento de las dislipemias. [citado 11 de noviembre de 2019]. Disponible en:\n                                                                                                                                                   https://manual.seen.es/article?id=5559fe85-9644-42fd-966a-6a43ac18103c\n                              IRC en estadio 3 o 4\n                            • Historia de ECV u hospitalización\n                              reciente por un SCA, evento coronario,                                                                         34  En relación con el tratamiento de la hiperlipidemia con estatinas, indique cuál\n       Riesgo muy             carotídeo o vascular periférico; riesgo                                                                             de las siguientes afirmaciones es verdadera:\n       alto                   CV a 10 años > 20%                                  <70             <100             <80\n                            • Diabetes o IRC estadio 3-4 con un FRCV                                                                             A. Las estatinas pueden ser utilizadas sin riesgo durante el embarazo.\n                              adicional\n                            • HFH sin ECV documentada                                                                                            B. En general, cuando se duplica la dosis de estatinas, se logra una reducción adicional\n                            • Dos o más FRCV y riesgo CV a 10 años                                                                                   de los niveles de colesterol de un 15%.\n       Riesgo alto            entre 10% y 20%                                     <100            <130             <90                           C. Las estatinas son especialmente útiles en las hiperlipidemias con colesterol VLDL\n                            • Diabetes o IRC en estadio 3-4 sin otros                                                                                elevado.\n                              FRCV\n       Riesgo               • Dos o menos FRCV y riesgo CV a 10                                                                                  D.  Fármacos metabolizados por el citocromo P450, como el ketoconazol, aumentan\n       moderado               años < 10%                                          <100            <130             <90                               los niveles plasmáticos\n######################\nOutput:", "parameters": {"model": "gpt-4o-mini", "temperature": 0.0, "frequency_penalty": 0.0, "presence_penalty": 0.0, "top_p": 1.0, "max_tokens": 4000, "n": 1}, "history": null}